Close

Top Stories

With 80 years of experience in water treatment and purification, the specialty chemicals company LANXESS with its Liquid Purification Technologies business unit (LPT), has a solid basis to appear at this year’s IFAT.

LANXESS India Private Limited, the leading specialty chemicals company has been acknowledged for its diligent adherence towards sustainable practices and concerted efforts in the field of corporate social responsibility (CSR), and has been conferred with the Indo-German Chamber of Commerce (IGCC) Award for ‘Outstanding Contribution towards best Sustainable Business Practices by a Large Enterprise’ for the year 2018 and the Indian Chemical Council (ICC) Award 2017 Certificate of Merit for Social Responsibility.

17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories

CluePoints, a leading provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, has announced the appointment of two industry thought-leaders to its senior team, as it continues its impressive global growth throughout North America, Europe and Asia Pacific.

CRF Health, a CRF Bracket company, the leading provider of patient-centered eSource technology solutions for the life sciences industry, unveiled details of its 2018 eCOA Forum.

IDIFARMA’s GMP spray drying technology for highly potent drugs up to Category 4 OEL/OEB is now operational.

Aptar Pharma, a leading provider of innovative drug delivery systems, will host a live educational webinar presenting the benefits of high quality film coated elastomeric components and the role they play in reducing patient and regulatory risk.

Bormioli Pharma, the world-renowned player in the healthcare packaging market, will attend to CPhI Worldwide, an established event that will provide the main actors of the pharmaceutical industry a great opportunity to meet and connect.

 Liver4Life is a project of Wyss Zurich, a joint research and development center of the ETH Zurich and the University of Zurich in the fields of Regenerative Medicine and Robotics. The project is aiming at developing a liver perfusion device.

Ahead of the inaugural edition of bioLIVE – the bioprocessing and manufacturing event opening October (9-11) in Madrid – CPhI Worldwide announces the bio findings of its annual report, which foresees much greater efficiency in bio-manufacturing and an increased exchange of ideas across small and large molecule industries.

Elligo Health Research, an integrated research organization, has added Dan Pucci, MBA, as vice president of strategic partnerships, and Michael A. Ibara, Pharm.D., as vice president of data sciences, to its executive leadership team.

The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D, has announced the results of a survey on the adoption of blockchain in the pharmaceutical and life science industries.

Specialty chemicals company LANXESS is continuing to invest in its global production network for high-performance plastics and is building another compounding facility at its Krefeld-Uerdingen site, Germany, for a mid double-digit million euro amount.

Thermo Fisher Scientific Inc., the world leader in serving science, announced its intent to open multiple Global Customer Solution Centers.

Pioneering partners Cmed and Innovative Physics have combined forces to showcase The Real Time Medical Imaging Users Tool Kit®, which uses artificial intelligence to support secure, rapid diagnostics in clinical trials, at DPharm 2018.

Specialty Chemicals Company LANXESS is to be represented in two Dow Jones Sustainability Indices again this year. Starting from September 24, 2018, LANXESS will be listed in the Dow Jones Sustainability Index (DJSI) World for the eighth time in a row.

Implandata Ophthalmic Products GmbH is pleased to announce that Dominick Arena is appointed as its Chairman of the Board effective immediately.

Recipharm, a leading contract development and manufacturing organisation (CDMO) has successfully received European Medicines Verification Organisation (EMVO) approval to submit serialisation data to the European Hub.

Athens Medical Group (AMG), including Athens Medical Center, joins Clinerion’s hospitals network, and expands Clinerion’s footprint in Western Europe.

Particle Sciences, a Lubrizol LifeSciences company and leading pharmaceutical contract development and manufacturing organization (CDMO), announces the appointment of Dr. Robert Lee to president.

Lonza announced the release of a new technical note that provides toxicity, wound healing and cosmetic researchers with a faster method for constructing three-dimensional (3D) full-thickness skin models that closely resemble native skin.

bioLIVE – the new bioprocessing and manufacturing event running alongside this year’s CPhI Worldwide announces the initial findings of the world’s first ever biopharma league table, which evaluates the reputations of major bio manufacturing countries across a number of characteristics (scored 1-10).

Ashfield, part of UDG Healthcare, a leading international healthcare services provider, has announced the appointment of Pierre Van Weperen as Commercial and Patient Solutions UK Managing Director.

The Active & Intelligent Packaging Industry Association, AIPIA, is delighted to announce that GlaxoSmithKline will be hosting this year’s AIPIA Congress Challenge.

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced its Russia compliance solution, providing companies with the ability to meet requirements for serialization, traceability, and compliance reporting in the Russian market, in advance of the country’s December 2019 enforcement deadline.

Smart Health Conference Dubai will bring together 500+ healthcare professionals from across the world on a common platform, at Raffles Dubai on the 13th and 14th of November, 2018.

Powder containment and aseptic transfer valve specialist, ChargePoint Technology has appointed Andrew McCreadie as their new business development manager for Europe, Middle East, India and Africa (EMEIA).

Codexis, Inc , a leading protein engineering company, announces the appointment of Hicham Alaoui, Ph.D. to the newly created position of Vice President, Biotherapeutics Research & Development.

STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, announces that its Active Pharmaceutical Ingredient (API) manufacturing facility at Jinshan (Shanghai, China) has successfully passed its fourth inspection from the U.S. FDA with no Form 483s issued. The site previously passed three FDA inspections in 2013, 2014 and 2016.

Dr. Kathleen Anne Welsh-Bohmer, a specialist in Alzheimer’s Disease (AD) research, has joined the scientific leadership team at NeuroCog Trials (NCT) as the Vice President of Neurodegenerative Disorders.

The filling and closing machine AFG 5000 from Bosch Packaging Technology recently received the internationally renowned “Red Dot Award” from the Design Zentrum Nordrhein-Westfalen in the category product design.

The Institut Pasteur officially unveiled its new Thermo Scientific Krios Cryo-TEM electron microscope at an event in Paris, France.

Access to good biomarkers is crucial in selecting the right patient groups for future clinical trials, thus increasing the likelihood that the study will succeed and, in the long run, allowing the development of effective treatment to combat severe cancers.

A report from bioLIVE – the new UBM biomanufacturing and bioprocessing event taking place in Madrid (October 9-11, 2018) – has collected findings from a panel of experts to identify a number of potential applications of small molecule expertise that should be applied to the biologics industry.

Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neuro degenerative therapeutics, announced that it has been awarded $3.4 million from the National Institute of NINDS in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

UBM India, India's leading B2B exhibition organizer, is all set to bring in the third edition of the widely appreciated India Pharma Week (IPW), a week-long celebration packed with avant-garde events from December 10-14, 2018 alongside its flagship expo CPhI & P-MEC India (December 12-14, 2018) to North India.

LANXESS is raising its prices for Durethan A (polyamide 6.6) compounds in Europe, Middle East and Africa by EUR 0.60/kg with immediate effect.

Progressive Care Inc. , a personalized healthcare services and technology company, launched a new program designed to educate patients and providers on treatment alternatives to opioids available through the company.

According to ISO annual survey published in November 2017, 1,025,761 certificates were issued based on ISO 9001:2008 but only 80,596 certificates based on the new ISO 9001:2015 during 2016.

SternMaid issued an invitation to an international symposium with scientific lectures, product tasting and a tour of the production facility.

As a groundbreaking innovation, Company EvCon - member of Cevital group - is exhibiting the UPWaterSystem on the process technology trade show ACHEMA 2018 in Frankfurt. The technology was developed in Germany and is based on the Vacuum Membrane Distillation Process.

In a recent study1 , scientists confirmed the ability of Omyapharm® to formulate orally disintegrating tablets (ODTs) with enhanced mouthfeel and examined their acceptability among healthy volunteers.

How can digital trends be used purposefully in regards to the application of injection systems? That is the key question being addressed by Vetter’s Open Innovation Challenge.

CRF Health, the leading provider of patient-centered eSource technology solutions for the life sciences industry, announced that it will host a series of interactive workshops and speaker sessions at DIA’s 2018 Global Annual Meeting, June 24-28, Boston, MA.

HIMSS Asia Pacific and Elsevier, the global information analytics company specializing in science and health, are proud to announce the call for submissions for the 6th Annual Asia Pacific (APAC) HIMSS-Elsevier Digital Healthcare Award 2018.

A survey of 229 life science professionals from The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, has found the majority (72%) believe their sector is lagging behind other industries in its development of AI.

Wize Pharma, Inc , a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced that it has signed an exclusive distribution agreement with HPGC Medical Co., Ltd.

Global benchmarking company STEM Healthcare (STEM) is pleased to announce the appointment of Tim Missey as US President effective June 4th 2018.

Moisture determination can benefit product quality at many stages of production including goods-in, in-process control, and final QC. Traditionally, oven-drying produced the reference method for these analyses.

Dr. Matthias L. Wolfgruber (64) is the new Chairman of the Supervisory Board of LANXESS AG.

DSCSA( Drug Supply chain Security Act):The bill was signed by President Obama on 27th November, 2013 to amend the federal Food, Drug and Cosmetic Act to grant the FDA with more authority to regulate and monitor the manufacturing of compounded drugs.

Bayer announced that the latest research across its growing oncology portfolio will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place June 1-5 in Chicago.

Celgene Corporation plans to present at four upcoming investor conferences and events where Celgene management will provide an overview of the Company.

Astellas Pharma Inc announced hat a wide selection of abstracts highlighting the Company's diverse oncology portfolio across a broad range of cancers have been accepted for oral and poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5 in Chicago.

Wieland Thermal Solutions at the ACHEMA 2018, hall 6.1, booth C4.Ulm, May 23rd - From 11th to 15th June the Achema, the World Forum and Leading Show for the Process Industries, will take place in Frankfurt.

Amgen announced a groundbreaking collaboration with the National Cancer Institute (NCI), the FCC Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Center and the University of California, San Diego (UCSD) Design Lab to support the improvement of cancer outcomes.

Working in a laboratory, especially when handling toxic substances, requires general precautions. Users should be properly trained and abide by certain rules to ensure safety for the entire lab.

USP compliance is essential for international pharmaceutical manufacturers and suppliers, particularly if they sell to the North American market. However, strict USP guidelines have also been adopted around the world.

Boehringer Ingelheim, the world’s second largest animal health company, has been boosting its investment in China by expanding the Asian Veterinary Research & Development (R&D) Center to enhance its research and innovation capacity.

Mitsubishi Tanabe Pharma Corporation MTPC announced that Canagliflozin received the Technology Award Grand Prize at the 50th JCIA Awards.

CPhI & P-MEC China (#CPhIChina) – organized by UBM and UBM SINEXPO – takes place at the Shanghai New International Expo Center (SNIEC) on 20-22nd June 2018.

GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipeline and early phase research programmes at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018.

TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced the latest keynote speakers for its upcoming FutureLink Munich conference to be held June 5-7, 2018.

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced the launch of a new online customer portal designed to enable customers to better monitor project progress and track communications.

Family-owned pharmaceutical company Boehringer Ingelheim presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim, Germany.

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and global biotechnology leader CSL Limited announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for Hereditary Angioedema (HAE) and other potential indications using CEVEC's proprietary CAP(R)Go technology.

On the occasion of its 20th anniversary, the Swiss Biotech Association launches Swiss Biotech Success Stories in recognition of the industry’s many accomplishments.

Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.

Bracket, a leading clinical trial technology and specialty services provider, has won the Best Patient-Focused Technological Development award at the Clinical and Research Excellence (CARE) Awards.

STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), announces that it has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center.

Vetter, a global leader in prefilled drug-delivery systems was paid a special visits at its Ravensburg, Germany facilities by Illinois Governor, Bruce Rauner.

CRF Health, the leading provider of patient-centered eSource for the life sciences industry, announced that its TrialMax Touch® and TrialMax Slate® solutions have been selected by a Global Category Japanese Pharmaceutical company for a significant pain trial.

Drug Safety 2018 aims to discuss the latest findings and current thinking on pharmacovigilance. Importantly, it will address the newest regulatory updates and interpretations of them, including the impact of the vital and much awaited Clinical Trial Regulations.

SMi are delighted to have our Chairman, Speaker and Workshop Host, Justin Mason-Home, Director, HPAPI Project Services Limited, onto the speaker panel for HPAPI 2018!

AstraZeneca presented new post-progression outcomes data from an exploratory analysis of the global Phase III FLAURA trial, which assessed the efficacy and safety of Tagrisso (osimertinib) as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Novartis announced a new post hoc analysis of the pivotal Phase III heart failure study, PARADIGM-HF, demonstrating that treatment with Entresto® (sacubitril/valsartan) helped to preserve kidney function, as assessed by estimated glomerular filtration rate (eGFR), in patients with heart failure with reduced ejection fraction (HFrEF).1

Hercules Pharmaceuticals, a Dutch biopharmaceutical company developing innovative anti-cancer drugs will present a poster, Poster LB-128, at the AACR meeting in Chicago on Monday April 16, 2018, from 8:00am-12:00pm, Poster section 45.

Powder containment and aseptic transfer valve specialist ChargePoint Technology, has appointed two new area managers to support the increased demand for its containment technologies and solutions throughout the US.

CPhI South East Asia organised by UBM has announced that from 2019 onwards it will alternate its annual location between the region’s two largest pharma economies, Indonesia and Thailand.

TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced the latest industry speakers confirmed for FutureLink Munich, which will occur June 6-7, 2018 at the Sheraton Munich Arabellapark Hotel.

Boehringer Ingelheim announced data from the landmark 52-week DYNAGITO® trial which show that in people with COPD (chronic obstructive pulmonary disease), Spiolto®Respimat® (tiotropium/olodaterol 5/5µg) lowers the rate of moderate-to-severe exacerbations compared with Spiriva® Respimat® (tiotropium).

METTLER TOLEDO is pleased to present a new poster entitled “10 Practical Tips for Correct Test Weight Handling” This free poster illustrates actions you can take to protect the accuracy of your test weights.

Aptar Pharma, a leading drug delivery systems provider, is proud to announce its leading role in the organization of the forthcoming 7th Innovative Drug Delivery Solutions Symposium (IDDS). The biennial conference is to be held this year at the SORL Hotel Hangzhou, Hangzhou, Chinafrom March 28-30, 2018.

Aptar Pharma, a leading global solution provider of innovative drug delivery systems, is pleased to be a Platinum Sponsor at RDD 2018, taking place from April 22 to April 26 at the JW Marriott Starr Pass Resort and Spa,Tucson, Arizona.

Vetter has won the 2018 ISPE Facility of the Year Award (FOYA) in the Facility of the Future category for its Center for Visual Inspection and Logistics.

Orchard Therapeutics, a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announced two key additions to its executive leadership team, appointing Jason Meyenburg as chief commercial officer and John Ilett as general counsel & company secretary.

New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA).1,2 The registry examined two-year safety and effectiveness outcomes of nearly 5,000 AF patients treated with dabigatran (marketed as Pradaxa®). Results of the completed Phase II of GLORIATM-AF,1 presented during the ‘Late-breaking science – Registries’ session, showed low rates of major bleeding (0.97%) and stroke (0.65%). These findings confirm the sustained safety and effectiveness of dabigatran and are highly consistent with the long-term safety profile observed in other real-world evidence, as well as in randomised clinical trials.

“Long-term, ‘real-world’ data are important to cardiologists as they help build a bigger picture of how an antithrombotic medication works in daily clinical practice,” commented Gregory Y H Lip, MD, Co-Chair of the GLORIATM-AF Steering Committee. “The results from the second phase of GLORIATM-AF underline the safety and effectiveness of dabigatran, which is reassuring for physicians treating patients with atrial fibrillation.”

In an additional analysis from GLORIATM-AF2 the safety of uninterrupted dabigatran for patients undergoing cardiovascular (CV) interventions was evaluated. The rates of major bleeding and stroke/ systemic embolism were very low, i.e. one major bleed and one systemic embolic event occurred in 412 CV interventions that were performed with uninterrupted dabigatran.

“From the first clinical trials such as RE-LY® and RELY-ABLE®, through to numerous real-world studies, both supported by and independent from Boehringer Ingelheim, we get an absolute, consistent picture of the favorable safety of dabigatran,” commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Recent clinical trials in specific settings like RE-CIRCUITTM,3 with dabigatran in AF patients undergoing cardio ablation, again demonstrated the superior safety of Pradaxa® compared to standard-of-care. The prospective, long-term data for dabigatran from GLORIATM-AF now add one further piece to complete this picture with profound real-world evidence.”

AF is the most common cardiac rhythm disorder worldwide, with numbers expected to rise in the coming years.4 Overall, people diagnosed with AF have a five-fold increased risk of stroke,5 which occurs when a blood clot blocks a vessel in the brain. Each year three million patients suffer AF-related strokes.6,7New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA).1,2 The registry examined two-year safety and effectiveness outcomes of nearly 5,000 AF patients treated with dabigatran (marketed as Pradaxa®). Results of the completed Phase II of GLORIATM-AF,1 presented during the ‘Late-breaking science – Registries’ session, showed low rates of major bleeding (0.97%) and stroke (0.65%). These findings confirm the sustained safety and effectiveness of dabigatran and are highly consistent with the long-term safety profile observed in other real-world evidence, as well as in randomised clinical trials.

“Long-term, ‘real-world’ data are important to cardiologists as they help build a bigger picture of how an antithrombotic medication works in daily clinical practice,” commented Gregory Y H Lip, MD, Co-Chair of the GLORIATM-AF Steering Committee. “The results from the second phase of GLORIATM-AF underline the safety and effectiveness of dabigatran, which is reassuring for physicians treating patients with atrial fibrillation.”

In an additional analysis from GLORIATM-AF2 the safety of uninterrupted dabigatran for patients undergoing cardiovascular (CV) interventions was evaluated. The rates of major bleeding and stroke/ systemic embolism were very low, i.e. one major bleed and one systemic embolic event occurred in 412 CV interventions that were performed with uninterrupted dabigatran.

“From the first clinical trials such as RE-LY® and RELY-ABLE®, through to numerous real-world studies, both supported by and independent from Boehringer Ingelheim, we get an absolute, consistent picture of the favorable safety of dabigatran,” commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Recent clinical trials in specific settings like RE-CIRCUITTM,3 with dabigatran in AF patients undergoing cardio ablation, again demonstrated the superior safety of Pradaxa® compared to standard-of-care. The prospective, long-term data for dabigatran from GLORIATM-AF now add one further piece to complete this picture with profound real-world evidence.”

AF is the most common cardiac rhythm disorder worldwide, with numbers expected to rise in the coming years.4 Overall, people diagnosed with AF have a five-fold increased risk of stroke,5 which occurs when a blood clot blocks a vessel in the brain. Each year three million patients suffer AF-related strokes.

SMi are delighted to present the 2nd annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) conference being held at Holiday Inn, Kensington Forum, London, on the 21st – 22nd May 2018.

The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, is calling upon the industry to support the ‘Lab of the Future’ (LoTF) through greater collaboration.

Increased international generic API companies and suppliers are reported at next month’s CPhI Japan 2018, traditionally an innovative drug focussed market, due to recent changes in the country.

Clinerion’s Board of Directors announces the appointment of Ian Rentsch as new CEO of the company, effective April 1, 2018.

Gilead Sciences, Inc. announced that Norbert Bischofberger, PhD, has decided to step down from his role as Executive Vice President, Research and Development and Chief Scientific Officer, effective at the end of April 2018.

Novartis announced changes to its senior leadership team to support the implementation of its strategic priorities. Bertrand Bodson, Chief Digital Officer, Steffen Lang, Global Head Novartis Technical Operations, and Shannon Klinger, Chief Ethics, Risk and Compliance Officer, have been appointed to the Executive Committee of Novartis (ECN).

Recipharm, the contract development and manufacturing organisation (CDMO), announces its new Blow-fill-seal machinery is now operational following a substantial investment last year at its facility in Kaysersberg, France.

An expert judging panel of IndustryWeek editors and advisors has selected the Thermo Fisher Scientific Auburn manufacturing site in Alabama as one of seven 2017 Best Plant winners.

Recipharm has announced that its 2017 International Environmental Award will be presented to Karen Kidd, Professor in Biology, and Geography & Earth Sciences at McMaster University in Hamilton, Ontario and Jarislowsky Chair in Environment and Health.

Powder containment and aseptic transfer valve specialist ChargePoint Technology has obtained the highest level of quality accreditation at its Liverpool, UK facility, to enable future product development for use in hazardous environments.

The pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India.

The Regulatory Affairs Professionals Society (RAPS) continues its support of medical device professionals in Europe with the launch of a workshop focused on 510(k) premarket submissions to the US Food and Drug Administration (FDA).

A small specialist British engineering company called Priorclave celebrates 30 years in the design, manufacture and world-wide supply of an extensive range of laboratory and research grade autoclaves.

Show more
Show less
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok